Prognostic Impact Of Esr1 Mutations In Er+Her2-Mbc Patients Prior Treated With First Line Ai And Palbociclib: An Exploratory Analysis Of The Pada-1 Trial.

Francois Clement Bidard,Celine Callens,Florence Dalenc,Barbara Pistilli,Thibault De La Motte Rouge,Florian Clatot,Veronique D'hondt,Luis Teixeira,Helene Vegas,Sibille Everhard,Jerome Lemonnier,Ivan Bieche,Anne Pradines, Jean FranCois Paitel,Dominique Spaeth,Isabelle Moullet,Jean-Yves Pierga,Frederique Berger,Anne-Claire Hardy-Bessard,Thomas Bachelot

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 50|浏览44

暂无评分

摘要

1010Background: The question of which is the best endocrine partner to CDK4/6 inhibitors in first line for ER+ HER2- metastatic breast cancer (MBC) remains open. ESR1 mutations might be of paramoun...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要